paltusotine
Sponsor Crinetics Pharmaceuticals, INC. · listed as CRNX
READOUT
Phase 3
Confidence: medium
Source: clinicaltrials
Next catalyst
Event typeREADOUT
Expected date2027-08-31
As disclosedAug 2027
Date precisionmonth
Confidencemedium
Trial & sponsor
Trial (NCT)NCT07087054
PhasePHASE3
StatusRECRUITING
Lead sponsorCrinetics Pharmaceuticals Inc.
Listed asCRNX
Condition(s)Carcinoid Syndrome; Carcinoid; Carcinoid Tumor; Carcinoid Tumor of Ileum; Carcinoid Tumor of Cecum; Carcinoid Tumor of Liver; Carcinoid Tumor of Pancreas; Carci…
!
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.
Get the full dataset — $499 → More CRNX catalysts